Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernewsroom.regeneron.com
Regeneron Pharmaceuticals Inc. News Releases
Get the latest updates from Regeneron Pharmaceuticals Inc. News Releases directly as they happen.
Follow now 149 followers
Latest posts
Last updated about 1 month ago
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026
about 1 month ago
TARRYTOWN, N.Y., March 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ...
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
about 1 month ago
Approval in moderate-to-severe patients was based on pivotal trial results showing over...
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment
about 2 months ago
$250,000 top award goes to Connor Hill in America’s longest running and...
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
about 2 months ago
Patients treated with olatorepatide achieved up to 19% body-weight loss at week...
Regeneron Announces Investor Conference Presentation
about 2 months ago
TARRYTOWN, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ...
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
about 2 months ago
If approved, Dupixent would be the first targeted medicine in the EU...
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
about 2 months ago
Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science...
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
2 months ago
Approval in adults and children aged 6 years and older supported by...
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
2 months ago
FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that...
Regeneron Announces Investor Conference Presentations
2 months ago
TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ...
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
2 months ago
36 abstracts to be presented across Regeneron -invented therapies, including first-time Phase...
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
3 months ago
New presentations include final 64-week results from the Phase 3 QUASAR trial...